Remdesivir

證據等級: L5

預測適應症: 6 個

Remdesivir: From COVID-19 to Multiple Endocrine Neoplasia

One-Sentence Summary

Remdesivir is a nucleotide prodrug antiviral originally developed and used for COVID-19 (and related viral infections such as Ebola). The TxGNN model’s top prediction is Multiple Endocrine Neoplasia (MEN), with a raw prediction score of 99.50%, but zero clinical trials and zero publications currently support this specific link — the prediction rationale itself flags this as likely knowledge-graph noise rather than a genuine repurposing signal.

Quick Overview

Item	Content
Original Indication	COVID-19 (not recorded in local regulatory licenses — drug is not currently marketed in this jurisdiction; based on public/clinical trial record)
Predicted New Indication	Multiple Endocrine Neoplasia
TxGNN Prediction Score	99.50%
Evidence Level	L5 (model prediction only, no supporting studies)
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, remdesivir is an adenosine nucleotide prodrug that inhibits the viral RNA-dependent RNA polymerase (RdRp), and its efficacy against SARS-CoV-2 (and Ebola virus) has been established through multiple completed Phase 3 trials.

For the top-ranked prediction, Multiple Endocrine Neoplasia (MEN), no biologically plausible mechanistic link exists. MEN is a hereditary endocrine tumour syndrome driven by RET or MEN1 gene mutations — an oncogenic/genetic pathway entirely unrelated to viral RdRp inhibition. The evidence pack itself explicitly characterizes this as a likely false-positive signal from the TxGNN knowledge graph, with no clinical trials or literature identified to support the association.

It is worth noting that a lower-ranked prediction (HIV infectious disease, rank 2) did return 10+ clinical trials and 20 publications, but closer inspection shows nearly all of this evidence actually concerns remdesivir’s use in COVID-19, not HIV — the model appears to have confused disease categories under a shared “infectious disease” label. This reinforces that, for this candidate, the top-ranked prediction should be treated with caution rather than acted upon.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

Remdesivir currently holds no marketing authorization records in this jurisdiction (total_licenses = 0, market status: Not Marketed). No license table is available to display.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication (Multiple Endocrine Neoplasia) has an evidence level of L5 — a model score with no corroborating clinical trials, literature, or plausible mechanism of action. The next-ranked signal (HIV) initially appears stronger (L2) but on inspection reflects a data/label mismatch with COVID-19 evidence rather than genuine HIV-specific support. No indication in this candidate set currently meets a bar sufficient to proceed.

To proceed, the following is needed:

Confirm and document remdesivir’s mechanism of action (MOA) from DrugBank or primary literature
Obtain TFDA/US labeling data (warnings, contraindications) to clear the blocking safety data gap (DG001)
Re-validate the HIV-labeled evidence set to separate true HIV-specific studies from COVID-19-related trials/literature that were miscategorized
If pursuing MEN or SIV/FIV signals further, commission a targeted literature/mechanism review before any trial design work, as no supporting evidence currently exists
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.